Last reviewed: June 20, 2026
Last updated: June 20, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme involved in cellular energy metabolism and mitochondrial function, while semaglutide (Wegovy) is a GLP-1 receptor agonist that reduces appetite and improves blood sugar control. Many patients wonder whether stacking NAD+ boosters with GLP-1 therapy creates a synergistic weight-loss effect, but clinical evidence remains limited.
Start a NAD+ protocol with PlexusDx
One all-inclusive price covers your online provider visit, prescription, medication, and shipping — no membership, no hidden fees. Complete a short intake and a licensed provider reviews your fit.
Start your intake →
How NAD+ Supports Metabolic Health During Weight Loss
NAD+ levels decline with age and metabolic stress, impacting mitochondrial energy production and cellular repair processes. During weight loss, the body shifts from glucose burning to fat utilization, placing increased demand on mitochondrial efficiency. Some researchers propose that maintaining adequate NAD+ may help preserve lean muscle mass and reduce metabolic adaptation (the body's natural tendency to slow metabolism when calories drop).
NAD+ boosters such as nicotinamide riboside (NR) and NMN (nicotinamide mononucleotide) have shown promise in animal models for improving insulin sensitivity and reducing inflammation. However, human randomized controlled trials specifically examining NAD+ supplementation during active weight loss remain sparse. Current evidence does not establish a clear, dose-dependent weight-loss benefit from NAD+ alone in overweight adults.
What Research Says About Combining NAD+ With Semaglutide
No published clinical trials have directly tested NAD+ plus semaglutide co-administration in humans. Theoretical mechanisms suggest that improved mitochondrial function could enhance the body's ability to mobilize and oxidize fat while on GLP-1 therapy, but this remains speculative. Both NAD+ and GLP-1 agonists activate pathways related to cellular stress resistance and autophagy, raising the question of additive or synergistic effects that have not yet been formally studied.
The lack of clinical data means combining these two interventions falls into the category of experimental stacking. Any decision to use NAD+ alongside prescription weight-loss medications should involve consultation with a healthcare provider. PlexusDx takes a different approach by using genetic testing to select dual-compound therapies proven to work together, such as GLP-Squared, which combines semaglutide and tirzepatide to target multiple metabolic pathways.
Why Dual-Compound Therapy May Outperform Single-Agent Plus Supplement Stacks
GLP-Squared Injection (PlexusDx) combines semaglutide and tirzepatide, two peptides with overlapping but distinct mechanisms. Tirzepatide is a GIP/GLP-1 co-agonist, meaning it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, while semaglutide targets GLP-1 alone. This dual activation engages multiple satiety pathways and may produce greater weight reduction than monotherapy in appropriate candidates.
The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to GLP-Squared or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
Safety Considerations: NAD+ Boosters and GLP-1 Therapy Together
NAD+ boosters are generally recognized as safe in healthy adults at standard doses, though nausea, flushing, and mild gastrointestinal upset have been reported. GLP-1 medications commonly cause nausea, vomiting, and constipation, particularly during dose escalation. Combining NAD+ supplements (which may cause GI effects) with semaglutide (which does the same) could theoretically compound side effects, though this has not been systematically documented.
Another consideration: NAD+ boosters may influence insulin sensitivity and glucose metabolism. Since semaglutide also improves insulin sensitivity, the combined effect is unknown and could theoretically increase hypoglycemia risk in patients with diabetes. Before adding NAD+ to any GLP-1 regimen, patients should inform their prescribing provider and monitor blood glucose closely if applicable. PlexusDx healthcare teams review all medications and supplements during intake to identify potential interactions.
PlexusDx Personalized Approach: Genetic Testing Over Supplement Stacking
The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.
This precision approach eliminates guesswork and supplement stacking. Patients receive compounded medications from licensed 503A pharmacies at transparent, flat-rate pricing ($129/mo to $349/mo depending on product selection). PlexusDx serves all 50 states with no insurance requirement, no membership fee, and HSA/FSA eligibility. A patient who might benefit from dual-compound therapy gets GLP-Squared instead of single-agent semaglutide plus unproven NAD+ boosters, improving efficacy and safety.
How Your Genetics Relate to GLP-1 Pathways
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The GLP-Squared is $289/mo month-to-month, or from $249/mo on the 3-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.
Frequently Asked Questions
Will adding NAD+ supplements to my Wegovy prescription help me lose more weight?
Evidence does not support NAD+ boosters as an effective weight-loss agent on their own, and no clinical trials have tested NAD+ plus semaglutide together. A more evidence-based approach is genetic testing to optimize your medication selection. PlexusDx Precision Peptide Genetic Test identifies whether dual-compound therapy (like GLP-Squared) will work better for your genetic profile than single-agent semaglutide alone.
What is the mechanism by which NAD+ could theoretically enhance GLP-1 therapy?
NAD+ supports mitochondrial function and cellular energy production, which may help preserve metabolic rate during calorie restriction. Both NAD+ and GLP-1 agonists activate autophagy and stress-resistance pathways, suggesting possible synergy. However, this theory has not been tested in humans, making it speculative rather than evidence-based guidance for treatment decisions.
How much does PlexusDx dual-compound therapy cost compared to adding supplements to Wegovy?
GLP-Squared Injection from PlexusDx is $289/mo month-to-month (or $249/mo on the 3-month plan) flat—meaning your price remains the same as your dose increases. This includes access to genetic-guided personalization and compounded medication from licensed 503A pharmacies. NAD+ supplements may cost $30–$100/month separately, but without proven synergy with GLP-1 therapy or clinical trial support.
Are there safety risks to combining NAD+ boosters with semaglutide?
Both NAD+ boosters and GLP-1 medications can cause nausea and gastrointestinal effects, which could compound when combined. NAD+ may also influence insulin sensitivity, potentially increasing hypoglycemia risk in diabetic patients taking semaglutide. Before adding NAD+ to any GLP-1 regimen, consult with your provider and monitor blood glucose if applicable.
How does the PlexusDx Precision Peptide Genetic Test determine if I need dual-compound therapy instead of single-agent medication plus supplements?
No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What Happens If You Drink Alcohol on Zepbound?
Ozempic Shortage: What to Do and Where to Turn